Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

British National Formulary

1958 • 2,539 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 • 764 citations

Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

2003 • 616 citations

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

2002 • 583 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 490 citations

Severe acute interstitial pneumonia and gefitinib

2003 • 445 citations

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

2003 • 271 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 244 citations

A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC)

2001 • 194 citations

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

2004 • 79 citations

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

2000 • 62 citations

Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer

2000 • 56 citations

A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously Untreated Inoperable (Stage IIIB/IV) Non-small Cell Lung Cancer

2000 • 50 citations

The Eastern Cooperative Oncology Group

1994 • 42 citations

A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer

2002 • 42 citations

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer

2001 • 41 citations

Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol®) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer

2001 • 16 citations

O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program

2003 • 14 citations

P-620 Gefitinib (‘Iressa’, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer (NSCLC)

2003 • 8 citations

Targeting the epidermal growth factor receptor: prognostic and clinical implications

2003 • 4 citations